Drug metabolism and personalized therapy最新文献_第2页

CYP2C19 genotype-phenotype correlation: current insights and unanswered questions. CYP2C19基因型-表型相关性：目前的见解和尚未解决的问题。

Drug metabolism and personalized therapy Pub Date : 2024-12-13 eCollection Date: 2024-12-01 DOI: 10.1515/dmpt-2024-0093

Nadine de Godoy Torso, Fernanda Rodrigues-Soares, Catalina Altamirano, Ronald Ramírez-Roa, Martha Sosa-Macías, Carlos Galavíz-Hernández, Enrique Terán, Eva Peñas-LLedó, Pedro Dorado, Adrián LLerena

引用次数: 0

UHPLC-MS/MS standardized extract of Vernonia amygdalina leaf inhibits CYP2C9 and CYP3A4 activities in hepatic cells of control and streptozotocin-induced diabetic rats. 苦杏仁叶UHPLC-MS/MS标准提取物抑制链脲霉素诱导的糖尿病大鼠肝细胞CYP2C9和CYP3A4活性。

Drug metabolism and personalized therapy Pub Date : 2024-12-12 eCollection Date: 2024-12-01 DOI: 10.1515/dmpt-2024-0005

Bassel Al Sabbagh, Vijayaraj Kumar Palanirajan, Yik-Ling Chew, Jin Han Chin, Mariam Ahmad, Gabriel Akyirem Akowuah

{"title":"UHPLC-MS/MS standardized extract of Vernonia amygdalina leaf inhibits CYP2C9 and CYP3A4 activities in hepatic cells of control and streptozotocin-induced diabetic rats.","authors":"Bassel Al Sabbagh, Vijayaraj Kumar Palanirajan, Yik-Ling Chew, Jin Han Chin, Mariam Ahmad, Gabriel Akyirem Akowuah","doi":"10.1515/dmpt-2024-0005","DOIUrl":"10.1515/dmpt-2024-0005","url":null,"abstract":"Objectives: Vernonia amygdalina Del. is a perennial tropical shrub from Asteraceae. The fresh leaf of V. amygdalina is consumed as a vegetable due to its medicinal and nutritional properties. The present study focused on the quantification of bioactive compounds, luteolin-7-O-glucoside, luteolin-7-O-glucuronide, and 1,5-O-dicaffeoylquinic acid from aqueous leaf extract of V. amygdalina. The study also aims to investigate the effects of the aqueous leaf extract of V. amygdalina on cytochrome P450 2C9 (CYP2C9), and cytochrome P450 3A4 (CYP3A4) in hepatic cells of control and diabetic rats.Methods: The quantification of the bioactive compounds was conducted using ultra-high-performance liquid chromatography multiple reactions monitoring tandem mass spectrometry (UHPLC-MS/MS-MRM) technique. The effect of the extract on CYP2C9 and CYP3A4 activities was determined using a fluorometric screening kit according to the manufacturer's instructions.Results: The three bioactive compounds were detected and quantified in the aqueous leaf extract. Results showed that the content of luteolin-7-O-glucuronide (47 μg/mg) was the highest followed by luteolin-7-O-glucoside (3.5 μg/mg) and 1,5-O-dicaffeoylquinic acid (1.07 μg/mg). The extract showed an inhibitory effect on CYP3A4 and CYP2C9 enzyme activities in control and diabetic rats.Conclusions: The UHPLC-MS/MS-MRM method is sensitive and reliable for the quality control of V. amygdalina leaf extract. The inhibitory effect of the extract suggests that concomitant use of V. amygdalina leaf preparations with conventional drugs metabolized and eliminated from the body by CYP3A4 and CYP2C9 enzymes may lead to possible interaction.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"231-241"},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives. 西班牙在临床实践中实施药物遗传学的现状：从地区到国家的举措。

Drug metabolism and personalized therapy Pub Date : 2024-11-11 eCollection Date: 2024-12-01 DOI: 10.1515/dmpt-2024-0042

Maria Apellaniz-Ruiz, Jordi Barrachina, Paula Castro-Sanchez, Ana Comes-Raga, Xandra García-González, Almudena Gil-Rodriguez, Elixabet Lopez-Lopez, Olalla Maroñas, Rocío Morón, Javier Muriel, Gladys G Olivera, Pau Riera, Miriam Saiz-Rodríguez, Sara Salvador-Martín, Carla Sans-Pola, Hugo Tejera-Pérez, Alejandro Velasco-Ruiz, Zoraida Verde, Daniel Wang, Ana E Rodríguez-Vicente, Rocio Nunez-Torres

{"title":"Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives.","authors":"Maria Apellaniz-Ruiz, Jordi Barrachina, Paula Castro-Sanchez, Ana Comes-Raga, Xandra García-González, Almudena Gil-Rodriguez, Elixabet Lopez-Lopez, Olalla Maroñas, Rocío Morón, Javier Muriel, Gladys G Olivera, Pau Riera, Miriam Saiz-Rodríguez, Sara Salvador-Martín, Carla Sans-Pola, Hugo Tejera-Pérez, Alejandro Velasco-Ruiz, Zoraida Verde, Daniel Wang, Ana E Rodríguez-Vicente, Rocio Nunez-Torres","doi":"10.1515/dmpt-2024-0042","DOIUrl":"10.1515/dmpt-2024-0042","url":null,"abstract":"Introduction: Pharmacogenetics (PGx) has the potential to improve patient care, allowing to transform medical interventions by providing personalized therapeutic strategies. Scientific evidence supports the use of PGx in clinical practice and international organizations are developing clinical guidelines to facilitate the utilization of PGx testing. However, clinical implementation of PGx is limited and unequal worldwide.Content: This review summarizes regional and national Spanish initiatives to implement PGx in the clinical practice.Summary and outlook: Diverse strategies to implement PGx in healthcare are applied across countries or even in the different regions of a specific country. Such was the case of Spain, a European country with 17 Autonomous Regions and two Autonomous Cities, each one with capacity to manage their own healthcare systems. Nevertheless, during the past years, many initiatives and strategies have been launched in Spain to develop different aspects of PGx. Importantly, the National Healthcare System has approved a PGx testing catalogue. This review highlights the crucial work and efforts of scientific societies (like the Spanish Society of Pharmacogenetics and Pharmacogenomics), of experts in PGx, of healthcare providers and of governmental parties in the implementation of PGx to personalize patient therapy, focused in Spain.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"183-199"},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of a polyherbal formulation in the management of Escherichia coli urinary tract infection. 治疗大肠杆菌尿路感染的多草药配方的有效性和安全性。

Drug metabolism and personalized therapy Pub Date : 2024-11-11 eCollection Date: 2024-12-01 DOI: 10.1515/dmpt-2024-0070

Almas Qureshi, Rais Ur Rahman, Yasmeen Shamsi

{"title":"Efficacy and safety of a polyherbal formulation in the management of Escherichia coli urinary tract infection.","authors":"Almas Qureshi, Rais Ur Rahman, Yasmeen Shamsi","doi":"10.1515/dmpt-2024-0070","DOIUrl":"10.1515/dmpt-2024-0070","url":null,"abstract":"Objectives: Urinary tract infection (UTI) is one of the most frequent reasons for prescribing antibiotics. Escherichia coli implicated in 75-90 % cases of UTI is becoming increasingly resistant to antibiotics. Finding alternative therapeutic agent for this infection is critical, for which herbal drugs may be an option. In Unani medicine, urinary tract infection (Ṭa'diya Majra-i-Bawl) is treated with herbal drugs possessing Da'fe Ufoonat (antiseptic), Muhallilat (anti-inflammatory) and Mudirrat (diuretic) properties. Polyherbal formulations of such drugs are expected to be beneficial in treating Escherichia coli infection. The aim of the study was to assess the efficacy and safety of a Unani polyherbal formulation aimed to develop a safe and efficacious drug for the treatment of urinary tract infection (Ṭa'diya Majra-i-Bawl) caused by Escherichia coli.Methods: This open-label, single armed clinical study was conducted on patients with clinical signs and symptoms of UTI and positive urine culture for E. coli. Patients were treated with the polyherbal formulation consisting of 50 % hydro-alcoholic extracts of Khar Khasak (Tribulus terrestris), Bhui Amla (Phyllanthus niruri), Kabab Cheeni (Piper cubeba), Beekh -i-Kasni (Cichorium intybus), Beekh-i-Karafs (Apium graveolens), Asl-us-Soos (Glycyrrhiza glabra), and Giloy (Tinospora cordifolia) in a dose of one capsule (500 mg) thrice a day orally with plain water for 42 days.Results: Maximum (83 %) urine cultures turned out negative for E. coli after the completion of therapy.Conclusions: Polyherbal Unani formulation was found to be very effective for the treatment of Urinary tract infection. Clinical and microbiological cure was achieved in maximum number of patients and drug was very well tolerated without any adverse/side effect.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"221-230"},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the therapeutic potential and personalized therapy of testosterone: a comprehensive review. 挖掘睾酮的治疗潜力和个性化疗法：全面综述。

Drug metabolism and personalized therapy Pub Date : 2024-11-06 eCollection Date: 2025-03-01 DOI: 10.1515/dmpt-2024-0035

Aditya V Reddy, Ramasamy Kesavan, Rajendran Priyadharsini, Reka Deva

{"title":"Unlocking the therapeutic potential and personalized therapy of testosterone: a comprehensive review.","authors":"Aditya V Reddy, Ramasamy Kesavan, Rajendran Priyadharsini, Reka Deva","doi":"10.1515/dmpt-2024-0035","DOIUrl":"10.1515/dmpt-2024-0035","url":null,"abstract":"Introduction: Testosterone, the primary male sex hormone, orchestrates various physiological processes including sex differentiation, development of male characteristics, sperm production, and fertility. Its synthesis primarily occurs in Leydig cells within the testes, with smaller contributions from the ovaries and adrenal glands, all derived from cholesterol. Current therapeutic use of testosterone is mainly confined to treating hypergonadotropic hypogonadism, with limited off-label usage for augmenting muscle growth.Content: This review delves into numerous studies investigating testosterone's therapeutic potential across various medical conditions as depicted in the figure given below.Summary: Of all the studies in this review, which show a positive therapeutic result by using testosterone, the most promising areas of potential usage of testosterone are anxiety and diabetes mellitus, followed by obesity and depression.Outlook: By the medium if this study, we want to not only enlist the various potential therapeutic uses of testosterone, but also promote a optimal hormonal balance, which can lead to prevention and/or better treatment outcomes for the mentioned diseases.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric pharmacogenetics: profiling CYP2C8 polymorphisms at King Abdulaziz University Dental Clinic. 儿科药物遗传学：阿卜杜勒-阿齐兹国王大学牙科诊所的 CYP2C8 多态性分析。

Drug metabolism and personalized therapy Pub Date : 2024-11-06 eCollection Date: 2024-12-01 DOI: 10.1515/dmpt-2024-0015

Amina M Bagher, Rania A Aboud, Noura M Alkinaidri, Saja A Aljilani, Rawan H Hareeri, Lenah S Binmahfouz, Sara M Bagher

{"title":"Pediatric pharmacogenetics: profiling CYP2C8 polymorphisms at King Abdulaziz University Dental Clinic.","authors":"Amina M Bagher, Rania A Aboud, Noura M Alkinaidri, Saja A Aljilani, Rawan H Hareeri, Lenah S Binmahfouz, Sara M Bagher","doi":"10.1515/dmpt-2024-0015","DOIUrl":"10.1515/dmpt-2024-0015","url":null,"abstract":"Objectives: Ibuprofen, a widely used non-steroidal anti-inflammatory (NSAID) for managing pain and inflammation in pediatric patients, is metabolized by the CYP2C8 enzyme. Studies suggest that the CYP2C8*2, *3, and *4 variations of the CYP2C8 gene diminish ibuprofen metabolism, increasing the risk of adverse reactions. The aim of this study was to determine the frequency of the CYP2C8*2, *3, and *4 alleles and genotypes in a pediatric population attending the King Abdulaziz University dental clinic and compare our findings to those of other populations.Methods: A cross-sectional study was conducted with 140 healthy Saudi children ages 6-12. Saliva samples were collected using Oragene™ DNA Sample Collection Kits and analyzed for polymorphisms using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).Results: The study identified that CYP2C8*2 AA, AT, and TT genotypes occurred at frequencies of 87.86 %, 9.29 %, and 2.86 %, respectively. For CYP2C8*3, AA, AG, and GG genotypes were found in 87.14 , 8.75, and 4.29 % of subjects, respectively. The CYP2C8*4 allele was less frequent, with CC and CG genotypes at 97.86 % and 2.14 %, respectively, and the GG genotype was absent. Allele frequencies for CYP2C8*2, *3, and *4 were 7.5 %, 8.57 %, and 1.07 %, respectively.Conclusions: Our findings reveal that the allelic frequencies for the CYP2C8 polymorphisms in the Saudi pediatric cohort are substantially elevated compared to those reported in other Asian populations. This suggests Saudis may experience more varied drug responses, especially for medications that undergo metabolism by the CYP2C8 enzyme, like ibuprofen.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"207-213"},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute and sub-chronic oral GLP toxicity of Withania somnifera root extract in Sprague Dawley rats. 睡茄根提取物对 Sprague Dawley 大鼠的急性和亚慢性口服 GLP 毒性。

Drug metabolism and personalized therapy Pub Date : 2024-10-02 DOI: 10.1515/dmdi-2024-0056

Pralhad Wangikar, Pradhnya Chaudhari, Eshita Sharma, Chhaya Godse, Ashit Vora, Sujit Nair

{"title":"Acute and sub-chronic oral GLP toxicity of Withania somnifera root extract in Sprague Dawley rats.","authors":"Pralhad Wangikar, Pradhnya Chaudhari, Eshita Sharma, Chhaya Godse, Ashit Vora, Sujit Nair","doi":"10.1515/dmdi-2024-0056","DOIUrl":"https://doi.org/10.1515/dmdi-2024-0056","url":null,"abstract":"Objectives: Withania somnifera (WS) is a valuable medicinal plant that has been used against several ailments. The medicinal properties of WS are ascribed to existence of secondary metabolites which are in great demand in herbal nutraceutical industry. Despite well-known therapeutic effects of WS, it is necessary to assess preclinical toxicity of WS plant on rats and further explore its potential application against treatment of various disorders in humans. The existing study assessed oral acute and sub-chronic toxicities of WS root extract in Sprague Dawley (SD) rats (male and female) for 14 and 90 days, respectively under OECD-423 and -408 guidelines as well as GLP compliance.Methods: In acute toxicity, rats of either sex were orally fed a dose of 2,000 mg/kg. In sub-chronic toxicity, animals were orally administered repeated doses of WS root extract at 250, 500, 1,000 mg/kg for 90 days with an additional 14-day recovery period. Two more groups (n=5 animals each) receiving vehicle and 1,000 mg/kg of WS root extract for 90 days were also observed.Results: In acute toxicity, the results revealed that LD50 of WS root extract in SD rats was higher than 2,000 mg/kg. In sub-chronic toxicity, oral administration of extract for 90 days showed no significant toxicological changes in rats. Haematological and serum chemistry markers were found within normal range. Terminal necropsy showed no gross or histopathological outcomes.Conclusions: The no-observed-adverse-effect level (NOAEL) of WS root extract was 1,000 mg/kg body weight, and safe to use at this dose in rats.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute and sub-chronic oral GLP toxicity of Withania somnifera root extract in Sprague Dawley rats. 睡茄根提取物对 Sprague Dawley 大鼠的急性和亚慢性口服 GLP 毒性。

Drug metabolism and personalized therapy Pub Date : 2024-10-02 eCollection Date: 2024-09-01 DOI: 10.1515/dmpt-2024-0056

Pralhad Wangikar, Pradhnya Chaudhari, Eshita Sharma, Chhaya Godse, Ashit Vora, Sujit Nair

{"title":"Acute and sub-chronic oral GLP toxicity of Withania somnifera root extract in Sprague Dawley rats.","authors":"Pralhad Wangikar, Pradhnya Chaudhari, Eshita Sharma, Chhaya Godse, Ashit Vora, Sujit Nair","doi":"10.1515/dmpt-2024-0056","DOIUrl":"10.1515/dmpt-2024-0056","url":null,"abstract":"Objectives: Withania somnifera (WS) is a valuable medicinal plant that has been used against several ailments. The medicinal properties of WS are ascribed to existence of secondary metabolites which are in great demand in herbal nutraceutical industry. Despite well-known therapeutic effects of WS, it is necessary to assess preclinical toxicity of WS plant on rats and further explore its potential application against treatment of various disorders in humans. The existing study assessed oral acute and sub-chronic toxicities of WS root extract in Sprague Dawley (SD) rats (male and female) for 14 and 90 days, respectively under OECD-423 and -408 guidelines as well as GLP compliance.Methods: In acute toxicity, rats of either sex were orally fed a dose of 2,000 mg/kg. In sub-chronic toxicity, animals were orally administered repeated doses of WS root extract at 250, 500, 1,000 mg/kg for 90 days with an additional 14-day recovery period. Two more groups (n=5 animals each) receiving vehicle and 1,000 mg/kg of WS root extract for 90 days were also observed.Results: In acute toxicity, the results revealed that LD50 of WS root extract in SD rats was higher than 2,000 mg/kg. In sub-chronic toxicity, oral administration of extract for 90 days showed no significant toxicological changes in rats. Haematological and serum chemistry markers were found within normal range. Terminal necropsy showed no gross or histopathological outcomes.Conclusions: The no-observed-adverse-effect level (NOAEL) of WS root extract was 1,000 mg/kg body weight, and safe to use at this dose in rats.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"145-158"},"PeriodicalIF":0.0,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current developments and advancements of 3-dimensional printing in personalized medication and drug screening. 三维打印在个性化用药和药物筛选方面的发展和进步。

Drug metabolism and personalized therapy Pub Date : 2024-09-30 eCollection Date: 2024-12-01 DOI: 10.1515/dmpt-2024-0024

Megha Tonk, Vishal Gupta, Amar Dhwaj, Monika Sachdeva

{"title":"Current developments and advancements of 3-dimensional printing in personalized medication and drug screening.","authors":"Megha Tonk, Vishal Gupta, Amar Dhwaj, Monika Sachdeva","doi":"10.1515/dmpt-2024-0024","DOIUrl":"10.1515/dmpt-2024-0024","url":null,"abstract":"Introduction: 3-Dimensional printing (3DP) is an additive manufacturing (AM) technique that is expanding quickly because of its low cost and excellent efficiency. The 3D printing industry grew by 19.5 % in 2021 in spite of the COVID-19 epidemic, and by 2026, the worldwide market is expected to be valued up to 37.2 billion US dollars.Content: Science Direct, Scopus, MEDLINE, EMBASE, PubMed, DOAJ, and other academic databases provide evidence of the increased interest in 3DP technology and innovative drug delivery approaches in recent times.Summary: In this review four main 3DP technologies that are appropriate for pharmaceutical applications: extrusion-based, powder-based, liquid-based, and sheet lamination-based systems are discussed. This study is focused on certain 3DP technologies that may be used to create dosage forms, pharmaceutical goods, and other items with broad regulatory acceptance and technological viability for use in commercial manufacturing. It also discusses pharmaceutical applications of 3DP in drug delivery and drug screening.Outlook: The pharmaceutical sector has seen the prospect of 3D printing in risk assessment, medical personalisation, and the manufacture of complicated dose formulas at a reasonable cost. AM has great promise to revolutionise the manufacturing and use of medicines, especially in the field of personalized medicine. The need to understand more about the potential applications of 3DP in medical and pharmacological contexts has grown over time.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"167-182"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential antibacterial effects of tea polyphenols. 茶多酚的潜在抗菌作用。

Drug metabolism and personalized therapy Pub Date : 2024-09-13 eCollection Date: 2024-09-01 DOI: 10.1515/dmpt-2024-0058

Aparna Shil, Arnab Banerjee, Jayati Roy, Manisha Pal, Debasmita Das, Rajarshi Paul, Bithin Kumar Maji, Mausumi Sikdar

{"title":"The potential antibacterial effects of tea polyphenols.","authors":"Aparna Shil, Arnab Banerjee, Jayati Roy, Manisha Pal, Debasmita Das, Rajarshi Paul, Bithin Kumar Maji, Mausumi Sikdar","doi":"10.1515/dmpt-2024-0058","DOIUrl":"10.1515/dmpt-2024-0058","url":null,"abstract":"The current review of tea and its parts is focused on the antibacterial properties, considering the possible applications and modes of action against bacterial illnesses. It shows the backdrop of antibiotic resistance and the huge demand for antibacterial treatments out there. From the interactions with bacterial components, the theory presented that tea polyphenols are antibacterial and therefore would be a substitute or supplementary therapy to the usual antibiotics. The study highlighted the role of tea polyphenols as potential antibacterial compounds that may interact with various bacterial components and different polyphenolic compounds occurring in tea. Future research directions may be directed toward testing more plant-based sources for antibacterial properties, in vivo validation of the studies, and possible synergistic effects with classical antibiotics. By addressing the controversies and disagreements involved, the present understanding of the topic of tea's antibacterial properties and enable the entry of new ways for fighting microorganisms resistant to antibiotics. In conclusion, this review adds to the growing body of evidence regarding the antimicrobial properties of tea and emphasizes the need for further studies that will allow the full exploitation of its therapeutic potential for countering the rising problem of antibiotic resistance in healthcare.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"103-114"},"PeriodicalIF":0.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0